Chronic Interferon-α Decreases Dopamine 2 Receptor Binding and Striatal Dopamine Release in Association with Anhedonia-Like Behavior in Nonhuman Primates

1] Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA [2] The Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (Impact Factor: 7.05). 05/2013; 38(11). DOI: 10.1038/npp.2013.115
Source: PubMed


Neuroimaging studies in humans have demonstrated that inflammatory cytokines target basal ganglia function and presynaptic dopamine (DA), leading to symptoms of depression. Cytokine-treated nonhuman primates also exhibit evidence of altered DA metabolism in association with depressive-like behaviors. To further examine cytokine effects on striatal DA function, eight rhesus monkeys (four male, four female) were administered interferon (IFN)-α (20 MIU/m2 s.c.) or saline for 4 weeks. In vivo microdialysis was used to investigate IFN-α effects on DA release in the striatum. In addition, positron emission tomography (PET) with [11C]raclopride was used to examine IFN-α-induced changes in DA2 receptor (D2R) binding potential before and after intravenous amphetamine administration. DA transporter binding was measured by PET using [18F]2β-carbomethoxy-3β-(4- chlorophenyl)-8-(2-fluoroethyl)nortropane. Anhedonialike behavior (sucrose consumption) was assessed during saline and IFN-α administration. In vivo microdialysis demonstrated decreased release of DA after 4 weeks of IFN-α administration compared with saline. PET neuroimaging also revealed decreased DA release after 4 weeks of IFN-α as evidenced by reduced displacement of [11C]raclopride following amphetamine administration. In addition, 4 weeks of IFN-α was associated with decreased D2R binding but no change in the DA transporter. Sucrose consumption was reduced during IFN-α administration and was correlated with decreased DA release at 4 weeks as measured by in vivo microdialysis. Taken together, these findings indicate that chronic peripheral IFN-α exposure reduces striatal DA release in association with anhedonia-like behavior in nonhuman primates. Future studies examining the mechanisms of cytokine effects on DA release and potential therapeutic strategies to reverse these changes are warranted. © 2013 American College of Neuropsychopharmacology. All rights reserved.

Download full-text


Available from: Jennifer C Felger, Sep 22, 2015
  • Source
    • "Interestingly, both studies found no relationship between circulating inflammatory markers and TSPO binding suggesting that circulating inflammatory markers may not reflect central processes and to some extent, may be independent of microglial processes. Our findings add to a handful of other studies that have demonstrated an association between systemic inflammation and molecular substrates of behaviour, in particular the dopaminergic system in primates and humans (Capuron et al., 2012; Felger et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Preclinical studies demonstrate that pro-inflammatory cytokines increase serotonin transporter availability and function, leading to depressive symptoms in rodent models. Herein we investigate associations between circulating inflammatory markers and brainstem serotonin transporter (5-HTT) availability in humans. We hypothesised that higher circulating inflammatory cytokine concentrations, particularly of tumour necrosis factor (TNF-α), would be associated with greater 5-HTT availability, and that TNF-α inhibition with etanercept (sTNFR:Fc) would in turn reduce 5-HTT availability. In 13 neurologically healthy adult women, plasma TNF-α correlated significantly with 5-HTT availability (rho=0.6; p=0.03) determined by [(123)I]-beta-CIT SPECT scanning. This association was replicated in an independent sample of 12 patients with psoriasis/psoriatic arthritis (rho=0.76; p=0.003). Indirect effects analysis, showed that there was a significant overlap in the variance explained by 5-HTT availability and TNF-α concentrations on BDI scores. Treatment with etanercept for 6-8weeks was associated with a significant reduction in 5-HTT availability (Z=2.09; p=0.03; r=0.6) consistent with a functional link. Our findings confirm an association between TNF-α and 5-HTT in both the basal physiological and pathological condition. Modulation of both TNF-α and 5-HTT by etanercept indicate the presence of a mechanistic pathway whereby circulating inflammatory cytokines are related to central nervous system substrates underlying major depression. Copyright © 2015. Published by Elsevier Inc.
    Brain Behavior and Immunity 08/2015; DOI:10.1016/j.bbi.2015.08.005 · 5.89 Impact Factor
  • Source
    • "However, 3 to 5 animals per group is common in nonhuman primate studies employing in vivo microdialysis techniques, and as with previous studies, a within-subject design was used to reduce effects of inter-subject variability and increase statistical power (Felger et al., 2013b). An additional limitation is that this study was designed to examine only whether the dopamine precursor L-DOPA could restore cytokine-induced reductions in dopamine release, which were previously found to correlate with decreases in effort-based sucrose consumption, a measure of anhedonia (Felger et al., 2013b). Future studies will be necessary to investigate whether restoration of dopamine release by agents that increase dopamine synthesis can reverse cytokine-related behavioral symptoms in humans or nonhuman primates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies using neuroimaging and in vivo microdialysis in humans and nonhuman primates indicate that inflammatory cytokines such as interferon-alpha reduce dopamine release in the ventral striatum in association with depressive symptoms including anhedonia and psychomotor slowing. Herein, we examined whether reduced striatal dopamine release in rhesus monkeys chronically treated with interferon-alpha can be restored by administration of the dopamine precursor levodopa via reverse in vivo microdialysis. Levodopa completely reversed interferon-alpha-induced reductions in striatal dopamine release. No changes were found in the 3,4-dihydroxyphenylacetic acid to dopamine ratio, which increases when unpackaged dopamine is metabolized via monoamine oxidase. These findings suggest that inflammatory cytokines reduce the availability of dopamine precursors without affecting end-product synthesis or vesicular packaging and/or release and provide the foundation for future studies investigating therapeutic strategies that facilitate availability of dopamine precursors to improve depressive symptoms in patient populations with increased inflammation. © The Author 2015. Published by Oxford University Press on behalf of CINP.
    The International Journal of Neuropsychopharmacology 01/2015; 18(4). DOI:10.1093/ijnp/pyu084 · 4.01 Impact Factor
  • Source
    • "Neuroimaging has therefore been employed as an aid to understanding the possible consequences of altered inflammatory and metabolic factors on neural systems [130,131]. Animal models suggest that elevations of peripheral cytokines and subsequent CNS microglia activation can disrupt the synthesis of both 5-HT and DA [132,133], and induce symptoms of fatigue and motivational anhedonia [134,135]. While direct evidence of increased microglia activity in MDD has not been detected using available PET ligands [136], functional neuroimaging studies have sought to better understand the downstream consequences of increased cytokine activity by examining correlations between peripheral cytokine levels and resting or task-induced fluctuations in Blood-Oxygen-Level Dependent (BOLD) signals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The neuroimaging literature of Major Depressive Disorder (MDD) has grown substantially over the last several decades, facilitating great advances in the identification of specific brain regions, neurotransmitter systems and networks associated with depressive illness. Despite this progress, fundamental questions remain about the pathophysiology and etiology of MDD. More importantly, this body of work has yet to directly influence clinical practice. It has long been a goal for the fields of clinical psychology and psychiatry to have a means of making objective diagnoses of mental disorders. Frustratingly little movement has been achieved on this front, however, and the 'gold-standard' of diagnostic validity and reliability remains expert consensus. In light of this challenge, the focus of the current review is to provide a critical summary of key findings from different neuroimaging approaches in MDD research, including structural, functional and neurochemical imaging studies. Following this summary, we discuss some of the current conceptual obstacles to better understanding the pathophysiology of depression, and conclude with recommendations for future neuroimaging research.
    Biology of Mood and Anxiety Disorders 03/2014; 4(1):5. DOI:10.1186/2045-5380-4-5
Show more